NewLimit is creating epigenetic reprogramming medications to cure diseases with significant unmet medical needs.
Biotechnology📍 South San Francisco, CAFounded 2021
Current Valuation
$1.6B
as of 2025-Q4
UNICORN
NewLimit is creating epigenetic reprogramming medications to cure diseases with significant unmet medical needs.
Company Profile
Founded
2021
HQ
South San Francisco, CA
Employees
43
Total Raised
$247.25M
Last Round
Early Stage VC — $45M (Oct 2025)
IPO Status
private
Fundraising Status
Early Stage VC · $45M · 10 mo ago
privateTotal raised $247.25M
Secondary Market
Implied price / share
$21.47
Open interest
5
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Early Stage VC
$45M
Oct 2025
—
$1.6B
Clinical TrialsHealth CareBiotechnology
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q4. Refreshed quarterly.